Printer Friendly

HYAL TO ENTER U.S. PHASE III TRIALS FOR TOPICAL PAIN PRODUCT

 MISSISSAUGA, Ontario, Aug. 31 /PRNewswire/ -- Hyal Pharmaceutical Corporation (NASDAQ-NMS: HYALF; TSE: HPC) announced today that its Investigational New Drug (IND) submission was accepted by the U.S. Food and Drug Administration (FDA). As a result, Hyal will begin its first U.S. Phase III clinical trials for HYAL AT2101, its product for the topical treatment of pain associated with arthritis, chronic soft tissue injuries, neuralgias and neuropathies. The company believes this product addresses a major market need that remains unfulfilled by currently available products and/or therapies.
 While the European and Asian markets for topical pain products containing NSAIDs are estimated at $1.2 billion, no version of these products is available in North America. Hyal's development program is designed to fulfill the clinical and regulatory requirements of not only the European and Asian authorities but also those in the U.S. This allows Hyal to pursue the unique market opportunity that exists in North America for topical NSAIDs.
 This Phase III trial will begin at the Arthritis Center in Phoenix, Ariz., and will assess the effectiveness of HYAL-AT2101 for the treatment of uncontrolled breakthrough pain associated with chronic osteoarthritis. 120 subjects will be evaluated using a double-blind, parallel, randomized, placebo controlled design.
 This significant advance in Hyal's clinical development program for HYAL AT2101, follows positive results announced last week in Paris at the Seventh World Congress on Pain. These results demonstrated the efficacy of this product in controlling intractable pain.
 Hyal is currently conducting Phase III clinical trials at a total of 14 independent centers in Canada, the U.S.A., Australia and a number of European countries for its three lead products: HYAL-CT1101 (also in U.S. Phase III) for the treatment of basal cell carcinoma, HYAL-AT2101 for the topical treatment of pain and HYAL-AV2201 for the intravenous treatment of moderate to severe pain.
 Hyal specializes in the development and worldwide commercialization of pharmaceutical formulations utilizing its proprietary Hyaluronic Acid based drug delivery technology. Hyal Pharmaceutical Corporation's shares are traded on the Toronto Stock Exchange under the trading symbol HPC and on NASDAQ National Market System under the trading symbol HYALF.
 -0- 8/31/93
 /CONTACT: Samuel S. Asculai, Ph.D., president and CEO, or David W. Harper, vice president development of Hyal Pharmaceutical, 416-366-4863; or Diane Perry, 212-661-8030, or Kathy Brunson, 312-266-7800, both of the Financial Relations Board/
 (HYALF)


CO: Hyal Pharmaceutical Corporation ST: Ontario IN: MTC SU: PDT

PS -- NY012 -- 9296 08/31/93 09:56 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 31, 1993
Words:411
Previous Article:PRINCETON DENTAL MANAGEMENT CORPORATION TO ACQUIRE DENTAL PRACTICES
Next Article:DESTEC ENERGY ACQUIRES NATURAL GAS RESERVES
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters